PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents growing 38.68% while TRAW's declined -21.67%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of TRAW's -14.24%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
Below half of TRAW's -14.38%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
101.21%
Below half TRAW's -3.99%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
Below half of TRAW's -3.30%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Below half of TRAW's -14.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-44.89%
Above 1.5x TRAW's -15.78%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Less than half of TRAW's -76.09%. David Dodd sees fewer expansions in other current obligations.
112.59%
Less than half of TRAW's -30.30%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Less than half of TRAW's -16.04%. David Dodd sees far fewer liability expansions relative to competitor.
-89.62%
Less than half of TRAW's 0.47%. David Dodd sees fewer share issuances vs. competitor.
-9.70%
1.25-1.5x TRAW's -6.76%. Bruce Berkowitz notes stronger reinvestment strategy.
98.99%
Similar yoy to TRAW's 105.56%. Walter Schloss sees parallel comprehensive income changes.
100.73%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-358.06%
≥ 1.5x TRAW's -14.30%. David Dodd sees stronger capital base growth than competitor.
42.36%
Below half TRAW's -14.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
Less than half of TRAW's 21.67%. David Dodd sees better deleveraging or stronger cash buildup than competitor.